SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Anuh Pharma surges on getting CEP for Sulfadimethoxine from EDQM

05 Dec 2025 Evaluate

Anuh Pharma is currently trading at Rs. 82.03, up by 2.87 points or 3.63% from its previous closing of Rs. 79.16 on the BSE.

The scrip opened at Rs. 79.30 and has touched a high and low of Rs. 83.25 and Rs. 79.00 respectively. So far 14891 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 121.00 on 20-Dec-2024 and a 52 week low of Rs. 74.03 on 18-Mar-2025.

Last one week high and low of the scrip stood at Rs. 83.25 and Rs. 78.27 respectively. The current market cap of the company is Rs. 824.14 crore.

The promoters holding in the company stood at 71.82%, while Non-Institutions held 28.18% in the company.  

Anuh Pharma has been granted the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for Sulfadimethoxine. This approval reinforces Anuh Pharma’s commitment to delivering high-quality Active Pharmaceutical Ingredients that adhere to the most stringent global regulatory standards. The CEP for Sulfadimethoxine will enable expanded access to regulated markets and support its customers with enhanced reliability, compliance, and supply security.

Established in 1960, Anuh Pharma is one of the largest manufacturers of Macrolides and Anti-TB products in India.

Anuh Pharma Share Price

82.80 0.08 (0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×